Is Lutikizumab, an Anti–Interleukin-1α/β Dual Variable Domain Immunoglobulin, efficacious for Osteoarthritis? Results from a bayesian network meta-analysis

Table 1

Characteristics of the included comparisons and the results of direct pair-wise meta-analysis (No. of pts: number of patients included; No. of trials: number of trials included into direct pair-wise meta-analysis; SMD: standardised mean difference; OR: odds ratio).

Comparison	No. of trials	No. of pts	Target joint	SMD (95% CI) for pain relief	SMD (95% CI) for function improvement	OR (95% CI) for withdrawal due to AEs	OR (95% CI) for serious AEs	OR (95% CI) for any drug-related AEs
ALI vs. PLA	2	478	Hand, hip, and knee	1.118 (-0.374 to 2.610)	0.992 (-0.433 to 2.417)	1.408 (0.647 to 3.061)	0.595 (0.211 to 1.681)	1.014 (0.732 to 1.405)
SCI vs. PLA	7	4402	Hip and knee	4.594 (2.381 to 6.807)	4.498 (2.402 to 6.594)	0.899 (0.631 to 1.282)	0.947 (0.329 to 2.727)	1.062 (0.890 to 1.267)
DUL vs. PLA	2	1247	Hip and knee	4.764 (3.895 to 5.632)	3.455 (2.470 to 4.440)	2.766 (1.721 to 4.445)	1.018 (0.309 to 3.352)	1.337 (1.098 to 1.627)
NSA vs. PLA	14	6305	Hand, hip and knee	2.688 (1.741 to 3.635)	2.849 (1.819 to 3.878)	1.473 (1.119 to 1.940)	1.758 (0.987 to 3.133)	1.332 (1.129 to 1.572)
OPI vs. PLA	2	2012	Hip and knee	1.914 (-2.833 to 6.660)	1.700 (-2.920 to 6.320)	2.419 (1.600 to 3.656)	1.012 (0.063 to 16.241)	1.281 (1.028 to 1.596)